AKR1C3在放疗食管癌患者病理标本检测中的意义  

Significance of AKR1C3 for esophageal cancer patients under radiotherapy

作　　者：赵静[1] 熊伟[2] 周德敏[3] 高献书[4] 任军[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院肿瘤科,北京100038 [2]唐山市人民医院肿瘤科,河北唐山063001 [3]北京大学医学部药学院,北京100191 [4]北京大学第一医院放射治疗科,北京100034

出　　处：《军事医学》2017年第6期494-497,共4页Military Medical Sciences

基　　金：国家自然科学基金资助项目(80172017)

摘　　要：目的对单纯放疗食管癌患者病理标本进行检测,评估醛固酮类还原酶家族1成员C3(AKR1C3)表达与放疗效果的关系。方法回顾性分析28例行单纯放疗的局部晚期食管癌患者的临床资料,通过免疫组化检测食管癌患者中AKR1C3的表达情况。结果 AKR1C3在不同分化程度的食管癌患者中表达程度不同,其表达水平与放疗短期疗效呈负相关(P=0.031,95%可信区间0.151~0.914)。结论 AKR1C3有可能成为食管癌放疗疗效判定的敏感性指标。Objective To evaluate the significance of the expression level of aldo-keto reductase family 1 member C3 （AKR1C3） for esophageal carcinoma patients treated with radiotherapy. Methods The clinical data of 28 patients with locally advanced esophageal carcinoma treated with radiotherapy alone was retrospectively analyzed, and the expression level of AKR1C3 was detected by immunohistochemistry. Statistical analysis was performed using SAS 8 statistical software, P 〈0.05 was considered statistically significant difference. Results The expression level of AKR1C3 was different in esophageal carcinoma patients at different levels of differentiation. The level of AKR1C3 expression was negatively correlated with efficacy of radiotherapy （ P = 0. 031, 95% CI 0. 151 - 0. 914 ）. Conclusion AKR1C3 can serve as a promising biomarker of the efficacy of radiotherapy for esophageal cancer.

关 键 词：食管肿瘤 放射疗法 AKR1C3 

分 类 号：R735.1[医药卫生—肿瘤]